Drugs in early clinical development for Systemic Lupus Erythematosus. - Wikidata - wikimedia - TriplyDB

Drugs in early clinical development for Systemic Lupus Erythematosus.

Drugs in early clinical development for Systemic Lupus Erythematosus.

http://www.wikidata.org/entity/Q37324772

about

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date An update on diet and nutritional factors in systemic lupus erythematosus management.Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy.

P2860

Q37709763-A673EACD-F221-491A-BEF4-878B4E0674B2 Q39178961-5CAA7108-392E-4940-B6AC-2133A0E28626 Q47108999-8E6F5CCB-1877-4E19-A3DA-67EFF03E1288 Q55409997-F4A53E33-D65D-41BE-81AB-7B91B387AE10

P2860

Drugs in early clinical development for Systemic Lupus Erythematosus.

http://www.wikidata.org/entity/Q37324772

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Drugs in early clinical development for Systemic Lupus Erythematosus.

@en

Drugs in early clinical development for Systemic Lupus Erythematosus.

@nl

type

label

Drugs in early clinical development for Systemic Lupus Erythematosus.

@en

Drugs in early clinical development for Systemic Lupus Erythematosus.

@nl

prefLabel

Drugs in early clinical development for Systemic Lupus Erythematosus.

@en

Drugs in early clinical development for Systemic Lupus Erythematosus.

@nl

P1433

Q37324772-E3B83506-8651-4D8D-A4EB-771ABABE2C55

P1476

Q37324772-B358A830-CD42-408C-8147-E181EFAD7786

P2093

Q37324772-042A81C6-3369-43A7-B7F4-CEB7DF74A7DD

Q37324772-180AF2A6-230E-4FB0-99F2-DBE79E291AEB

Q37324772-62519A73-6B25-494E-A8DF-C52487578546

Q37324772-6320F097-408A-464C-9A81-19963BEC225B

P2860

Q37324772-00BD1BF4-7AE2-4BF7-85F2-BAE4209903F5

Q37324772-01CA4EFB-EAA9-4C0A-98E1-CA35CD90F6DB

Q37324772-03AA7ACD-F836-4B8B-B68B-FE103A14947E

Q37324772-06E31939-71AD-4852-8328-E9332CA66856

Q37324772-0A880EA4-667A-4FD9-88BE-9A6E277CDF8C

Q37324772-0C920154-2056-453D-8FA5-954E5B811038

Q37324772-0DA7A0E0-B4B3-4560-9CF5-8B44C0BC9DD6

Q37324772-183825E5-9FC7-4757-AF04-485E76AA4959

Q37324772-1AAE339F-A9D1-42BD-A161-0A08CDDDAB7F

Q37324772-1B78984B-7580-4B90-8E49-4D5531EC6BFC

P304

Q37324772-18F470A8-EDD4-4A3A-B477-406AF3D3D815

P31

Q37324772-6F217EE9-7089-47A5-9667-CA9446E8BAD3

P356

Q37324772-E4F80106-C6A2-4089-B4F0-E5A5B0C3B596

P407

Q37324772-28D5D1BE-18EC-47DE-A1A6-71699EE16A30

P433

Q37324772-DE5A4EC0-6E96-468E-A862-86DE8CF3580F

P478

Q37324772-493A3079-3738-468D-8141-6CC6B7856562

P577

Q37324772-2D6139CB-5E30-4A7D-8057-743EA5CDC3B3

P698

Q37324772-F117C386-ECE2-4086-ABCF-092E00C2A512

P932

Q37324772-AFA9A31F-5CCB-4761-B5A7-EC79F9273EE9

P356

13543784.2016.1162291

P1433

Expert Opinion on Investigational Drugs

P1476

Drugs in early clinical development for Systemic Lupus Erythematosus.

@en

P2093

Mariana Postal

http://www.w3.org/2001/XMLSchema#string

Nailú Angélica Sinicato

http://www.w3.org/2001/XMLSchema#string

Simone Appenzeller

http://www.w3.org/2001/XMLSchema#string

Timothy B Niewold

http://www.w3.org/2001/XMLSchema#string

P2860

Obinutuzumab in hematologic malignancies: lessons learned to date

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

Long-term data on tacrolimus treatment in lupus nephritis.

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Antimalarials--the 'real' advance in lupus.

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

P304

573-583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2016.1162291

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26950689

http://www.w3.org/2001/XMLSchema#string

P932

5056793

http://www.w3.org/2001/XMLSchema#string